Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 131, Issue 11, Pages 2693-2703
Publisher
Wiley
Online
2012-04-05
DOI
10.1002/ijc.27579
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
- (2012) K. E. Hook et al. MOLECULAR CANCER THERAPEUTICS
- The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
- (2012) V. Sehdev et al. MOLECULAR CANCER THERAPEUTICS
- Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells
- (2011) Chun Chi Wu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
- (2011) Wenqing Qi et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
- (2011) Hernan Carol et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting Aurora Kinases in Cancer Treatment
- (2011) Kevin R. Kelly et al. CURRENT DRUG TARGETS
- Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells
- (2011) Kazuya Sumi et al. FEBS LETTERS
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
- (2010) H. Kantarjian et al. BLOOD
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
- (2010) R. T. Swords et al. BLOOD
- Aurora-A Is Essential for the Tumorigenic Capacity and Chemoresistance of Colorectal Cancer Stem Cells
- (2010) Patrizia Cammareri et al. CANCER RESEARCH
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
- (2010) Kevin R. Kelly et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia
- (2010) Antonio R. Lucena-Araujo et al. LEUKEMIA RESEARCH
- Aurora kinase A is a target of Wnt/ -catenin involved in multiple myeloma disease progression
- (2009) J. Dutta-Simmons et al. BLOOD
- KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
- (2009) Y. Shiotsu et al. BLOOD
- AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo
- (2009) A. Oke et al. CANCER RESEARCH
- A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer
- (2009) J.-Y. Yang et al. CLINICAL CANCER RESEARCH
- The regulatory function of umbilical cord blood CD4+ CD25+T cells stimulated with anti-CD3/anti-CD28 and exogenous interleukin (IL)-2 or IL-15
- (2009) Chen-Cheng Lee et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
- (2008) Y. Dai et al. BLOOD
- Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA
- (2008) S. T. Nawrocki et al. BLOOD
- Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia
- (2008) K. Kojima et al. BLOOD
- The Novel Polyamine Analogue CGC-11093 Enhances the Antimyeloma Activity of Bortezomib
- (2008) J. S. Carew et al. CANCER RESEARCH
- Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
- (2008) W. Fiskus et al. CLINICAL CANCER RESEARCH
- OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins
- (2008) Kenneth Maiese et al. TRENDS IN MOLECULAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now